Daratumumab, an anti-CD38 antibody, is used experimentally in the treatment of relapsed acute lymphoblastic leukemia (ALL). We treated five patients suffering from relapsed ALL with daratumumab. Four patients had T ALL, three of whom achieved complete remission (CR) after treatment and underwent stem cell transplant (SCT). Two of them had a second relapse and died 6 and 8 months after SCT, respectively. One transplanted T ALL patient remained in CR2 15 months after relapse. In the remaining T-ALL patient, the disease progressed under daratumumab treatment, and the patient died early after the first relapse. The B-cell precursor ALL patient with a second CD19-negative relapse, whose disease turned out to be resistant to the combination of daratumumab with chemotherapy, later achieved CR3 with inotuzumab ozogamicin, underwent SCT and remained in CR3. Leukemia burden should be monitored after daratumumab, and care should be taken not to misclassify leukemic cells with false negativity of surface CD38; using an antibody reacting with nondaratumumab epitopes is advantageous.

Department of Pediatric Hematology and Oncology Charles University 2nd Faculty of Medicine CLIP Prague Czech Republic

Department of Pediatric Hematology and Oncology Motol University Hospital Prague Czech Republic

Zobrazit více v PubMed

Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):34-44. https://doi.org/10.1182/blood-2016-03-705210

Bras AE, Beishuizen A, Langerak AW, et al. CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. Br J Haematol. 2018;180(2):292-296. https://doi.org/10.1111/BJH.14310

Minarik J, Novak M, Flodr P, et al. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. Eur J Haematol. 2017;99(2):186-189. https://doi.org/10.1111/EJH.12902

Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23(24):7498-7511. https://doi.org/10.1158/1078-0432.CCR-17-2027

Nijhof IS, Casneuf T, Van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959-970. https://doi.org/10.1182/BLOOD-2016-03-703439

Patiño-Escobar B, Ramos R, Linares M, Mejía A, Alcalá S. CD38: from positive to negative expression after daratumumab treatment. Cureus. 2020;12(4). https://doi.org/10.7759/CUREUS.7627